22.08
+1.46(+7.08%)
Currency In USD
| Previous Close | 20.62 |
| Open | 20.37 |
| Day High | 23.42 |
| Day Low | 20.35 |
| 52-Week High | 29.27 |
| 52-Week Low | 6.2 |
| Volume | 822,588 |
| Average Volume | 96,927 |
| Market Cap | 244.11M |
| PE | -10.62 |
| EPS | -2.08 |
| Moving Average 50 Days | 23.63 |
| Moving Average 200 Days | 19.23 |
| Change | 1.46 |
If you invested $1000 in Palvella Therapeutics, Inc. (PVLA) since IPO date, it would be worth $1,298.82 as of June 29, 2025 at a share price of $22.08. Whereas If you bought $1000 worth of Palvella Therapeutics, Inc. (PVLA) shares 0 years ago, it would be worth $1,298.82 as of June 29, 2025 at a share price of $22.08.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Palvella Therapeutics Completes Enrollment in Phase 3 SELVA Trial of QTORIN™ Rapamycin for Microcystic Lymphatic Malformations, Exceeding Enrollment Target by Over 25%
GlobeNewswire Inc.
Jun 23, 2025 11:30 AM GMT
Enrollment of 51 subjects highlights significant unmet need in this serious, lifelong genetic disease which currently has no FDA-approved therapies Top-line data expected in the first quarter of 2026 WAYNE, Pa., June 23, 2025 (GLOBE NEWSWIRE) -- (N
Palvella Therapeutics Granted Sixth U.S. Patent Covering 0.1–20% Anhydrous Compositions of Rapamycin and Other mTOR Inhibitors
GlobeNewswire Inc.
Jun 18, 2025 11:30 AM GMT
New intellectual property builds on Palvella’s multi-layered exclusivity strategy Patent term expected through at least 2038 WAYNE, Pa., June 18, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: PVLA) Palvella Therapeutics, Inc. (Palvella), a clinical-stage bioph
Palvella Therapeutics Receives Initial Proceeds from FDA Orphan Products Grant to Support Phase 3 SELVA Trial of QTORIN™ Rapamycin for Microcystic Lymphatic Malformations
GlobeNewswire Inc.
Jun 09, 2025 11:30 AM GMT
FDA Orphan Products Grants are awarded based on rigorous scientific and technical review by rare disease and regulatory experts Up to $2.6 million in non-dilutive funding anticipated over the grant period Top-line data from SELVA expected in the firs